LTC3057969I2 - Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit - Google Patents

Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit

Info

Publication number
LTC3057969I2
LTC3057969I2 LTPA2021003C LTPA2021003C LTC3057969I2 LT C3057969 I2 LTC3057969 I2 LT C3057969I2 LT PA2021003 C LTPA2021003 C LT PA2021003C LT PA2021003 C LTPA2021003 C LT PA2021003C LT C3057969 I2 LTC3057969 I2 LT C3057969I2
Authority
LT
Lithuania
Prior art keywords
kit
treatment
disorders associated
compositions used
compositions
Prior art date
Application number
LTPA2021003C
Other languages
English (en)
Original Assignee
Blueprint Medicines Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corporation filed Critical Blueprint Medicines Corporation
Publication of LTPA2021003I1 publication Critical patent/LTPA2021003I1/lt
Publication of LTC3057969I2 publication Critical patent/LTC3057969I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LTPA2021003C 2013-10-17 2021-03-16 Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit LTC3057969I2 (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361892086P 2013-10-17 2013-10-17
US201461931204P 2014-01-24 2014-01-24
US201461975229P 2014-04-04 2014-04-04
PCT/US2014/060746 WO2015057873A1 (en) 2013-10-17 2014-10-15 Compositions useful for treating disorders related to kit

Publications (2)

Publication Number Publication Date
LTPA2021003I1 LTPA2021003I1 (lt) 2021-04-12
LTC3057969I2 true LTC3057969I2 (lt) 2022-09-26

Family

ID=51904226

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14799576.5T LT3057969T (lt) 2013-10-17 2014-10-15 Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
LTPA2021003C LTC3057969I2 (lt) 2013-10-17 2021-03-16 Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP14799576.5T LT3057969T (lt) 2013-10-17 2014-10-15 Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit

Country Status (30)

Country Link
US (7) US9200002B2 (lt)
EP (2) EP3409674B1 (lt)
JP (2) JP6446040B2 (lt)
KR (1) KR102378689B1 (lt)
CN (2) CN110003217B (lt)
AU (1) AU2014337314B2 (lt)
BR (1) BR112016008541B1 (lt)
CA (1) CA2926999C (lt)
CY (2) CY1121182T1 (lt)
DK (1) DK3057969T3 (lt)
ES (2) ES2923888T3 (lt)
HR (1) HRP20181388T1 (lt)
HU (3) HUE039687T2 (lt)
IL (1) IL244677B (lt)
LT (2) LT3057969T (lt)
MX (1) MX365614B (lt)
NL (1) NL301094I2 (lt)
NO (1) NO2021012I1 (lt)
PH (1) PH12016500611A1 (lt)
PL (2) PL3409674T3 (lt)
PT (2) PT3409674T (lt)
RS (1) RS57542B1 (lt)
RU (1) RU2706235C2 (lt)
SG (1) SG11201602937UA (lt)
SI (1) SI3057969T1 (lt)
SM (1) SMT201800448T1 (lt)
TW (1) TWI683814B (lt)
UY (1) UY35787A (lt)
WO (1) WO2015057873A1 (lt)
ZA (1) ZA201601970B (lt)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
JP6576325B2 (ja) 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー ヘテロアリール化合物およびそれらの使用
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
FR3008779B1 (fr) 2013-07-19 2018-01-26 Areva Np Barre antivibratoire pour faisceau de tubes d'un generateur de vapeur
LT3057969T (lt) 2013-10-17 2018-07-10 Blueprint Medicines Corporation Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
DK3395814T3 (da) 2013-10-25 2022-07-04 Blueprint Medicines Corp Hæmmere af fibroblastvækstfaktorreceptoren
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
CN106231901A (zh) * 2014-04-15 2016-12-14 美国陶氏益农公司 作为杀真菌剂的金属酶抑制剂化合物
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
NZ742351A (en) 2015-11-02 2023-03-31 Blueprint Medicines Corp Inhibitors of ret
MX2018006195A (es) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
ES2987501T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Métodos de tratamiento de cánceres pediátricos
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
AU2017246554B2 (en) 2016-04-04 2022-08-18 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) * 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CN108191874B (zh) * 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3773589B1 (en) 2018-04-03 2023-11-01 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
EP3782998B1 (en) * 2018-04-16 2023-05-10 Shenzhen TargetRx, Inc. Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof
ES2969089T3 (es) 2018-06-22 2024-05-16 Com Innvento S A Artículo filtrante-absorbente multicapa; proceso para obtener dicho artículo; y uso del mismo
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
US20220010382A1 (en) 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
CN109232583A (zh) * 2018-11-29 2019-01-18 尚科生物医药（上海）有限公司 一种6-溴-3H-吡咯并[2,1-f][1,2,4]三嗪-4-酮的制备方法
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
CN111410648B (zh) * 2019-01-07 2024-03-29 浙江海正药业股份有限公司 一种手性c-KIT抑制剂药物关键中间体及其制备方法
EP4424312A3 (en) * 2019-04-12 2025-01-08 Blueprint Medicines Corporation Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
ES2966512T3 (es) * 2019-04-12 2024-04-22 Blueprint Medicines Corp Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración
CA3135240A1 (en) 2019-05-21 2020-11-26 Philip James Pye Processes and intermediates for preparing a btk inhibitor
CN114341138A (zh) * 2019-07-09 2022-04-12 桑多斯股份公司 口服可用的选择性kit和pdgfr激酶抑制剂的晶型
US20240075041A1 (en) 2019-10-04 2024-03-07 Blueprint Medicines Corporation Treatment of eosinophilic disorders with avapritinib
GB201915447D0 (en) 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs
US20220370465A1 (en) * 2019-11-04 2022-11-24 Blueprint Medicines Corporation Treatment of mast cell diseases and eosinophilic disorders
EP4069369A4 (en) 2019-12-06 2024-02-14 Schrödinger, Inc. CYCLIC COMPOUNDS AND METHODS OF USE
CN110938077B (zh) * 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
CN110950872A (zh) * 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
IL294214B2 (en) 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods for using them
WO2021183709A1 (en) 2020-03-11 2021-09-16 Teva Czech Industries S.R.O Solid state forms of avapritinib and process for preparation thereof
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
EP4168119A1 (en) 2020-06-17 2023-04-26 Teva Czech Industries s.r.o. Solid state forms of avapritinib salts
WO2022031576A1 (en) 2020-08-03 2022-02-10 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
JP2023541047A (ja) 2020-09-10 2023-09-27 シュレーディンガー， インコーポレイテッド がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
JP7828959B2 (ja) * 2020-10-14 2026-03-12 ブループリント メディシンズ コーポレイション Ｋｉｔおよびｐｄｇｆｒａ媒介疾患を処置するための組成物および方法
US20230391780A1 (en) 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
CN112552339A (zh) * 2020-12-10 2021-03-26 安徽昊帆生物有限公司 一种o-二苯基磷酰羟胺的制备方法
JP2024505890A (ja) 2021-01-26 2024-02-08 シュレーディンガー， インコーポレイテッド がん、自己免疫及び炎症性障害の治療に有用な三環式化合物
HU231413B1 (hu) 2021-02-26 2023-08-28 Egis Gyógyszergyár Zrt. Eljárás avapritinib és intermedierek előállítására
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
CN113686987B (zh) * 2021-08-19 2022-04-26 海南医学院 一种用于检测Avapritinib中间体中对映异构体的方法
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
US20250270190A1 (en) * 2022-04-19 2025-08-28 Blueprint Medicines Corporation Kit inhibitors
US20240382493A1 (en) * 2023-05-18 2024-11-21 Blueprint Medicines Corporation Methods for treating systemic mastocytosis and gastrointestinal stromal tumors
WO2024249855A1 (en) * 2023-06-02 2024-12-05 Idrx, Inc. Combination therapy comprising kit inhibitors for use in the treatment of cancer
CN122003418A (zh) 2023-09-11 2026-05-08 薛定谔公司 作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物
WO2025170989A1 (en) 2024-02-05 2025-08-14 Blueprint Medicines Corporation High-risk disease features of indolent systemic mastocytosis and methods for treating

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CZ303660B6 (cs) * 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
JP2003511378A (ja) 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JP3481930B2 (ja) 2000-03-30 2003-12-22 塩野義製薬株式会社 縮合イミダゾピリジン誘導体の新規製造法および新規結晶形
US6784603B2 (en) * 2001-07-20 2004-08-31 Teledyne Lighting And Display Products, Inc. Fluorescent lighting apparatus
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1497019B1 (en) 2002-04-23 2015-05-20 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
NZ541836A (en) * 2003-02-27 2008-12-24 Palau Pharma Sa Pyrazolopyridine derivatives
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
EP1755607A2 (en) 2004-04-29 2007-02-28 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JP5116687B2 (ja) * 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
US7348325B2 (en) * 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PL1973910T3 (pl) * 2006-01-27 2013-11-29 Shanghai hengrui pharmaceutical co ltd Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej
CN101007814A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯并六元杂环化合物及其在医药上的用途
CN101511835B (zh) * 2006-07-07 2013-11-27 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂
CN101808693A (zh) 2007-07-25 2010-08-18 百时美施贵宝公司 三嗪激酶抑制剂
JP2011515401A (ja) 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
KR20100003912A (ko) 2008-07-02 2010-01-12 삼성전자주식회사 동일 포맷의 미디어 파일 간에 미디어 정보 호환이 가능한미디어 파일을 생성하는 방법 및 장치와 미디어 파일을실행하는 방법 및 장치
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
WO2010144345A1 (en) 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2013519732A (ja) 2010-02-17 2013-05-30 アムジエン・インコーポレーテツド 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体
WO2012027495A1 (en) * 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
MX2013006768A (es) * 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
CN104981247A (zh) 2012-09-06 2015-10-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
SMT201800230T1 (it) 2012-12-21 2018-07-17 Plexxikon Inc Composti e metodi per la modulazione della chinasi e loro indicazioni
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
LT3057969T (lt) 2013-10-17 2018-07-10 Blueprint Medicines Corporation Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
DK3395814T3 (da) 2013-10-25 2022-07-04 Blueprint Medicines Corp Hæmmere af fibroblastvækstfaktorreceptoren
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
US20170119760A1 (en) 2015-10-28 2017-05-04 Ab Science Use of masitinib for the treatment of progressive supranuclear palsy
NZ742351A (en) 2015-11-02 2023-03-31 Blueprint Medicines Corp Inhibitors of ret
MX2018006195A (es) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of triazolopyrimidine compound
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
US20220010382A1 (en) 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
ES2966512T3 (es) 2019-04-12 2024-04-22 Blueprint Medicines Corp Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración
US20240075041A1 (en) 2019-10-04 2024-03-07 Blueprint Medicines Corporation Treatment of eosinophilic disorders with avapritinib
US20220370465A1 (en) 2019-11-04 2022-11-24 Blueprint Medicines Corporation Treatment of mast cell diseases and eosinophilic disorders
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
CN112223217A (zh) 2020-09-10 2021-01-15 中铁建设集团有限公司 一种新型拔钉器

Also Published As

Publication number Publication date
EP3409674A1 (en) 2018-12-05
EP3409674B1 (en) 2022-04-06
EP3057969B1 (en) 2018-06-13
PL3409674T3 (pl) 2022-09-26
RU2016118768A (ru) 2017-11-22
PT3057969T (pt) 2018-07-11
JP2016538257A (ja) 2016-12-08
CN110003217A (zh) 2019-07-12
SI3057969T1 (sl) 2018-10-30
SG11201602937UA (en) 2016-05-30
US20160102097A1 (en) 2016-04-14
CY2021007I1 (el) 2021-06-25
US9944651B2 (en) 2018-04-17
BR112016008541B1 (pt) 2022-11-22
PT3409674T (pt) 2022-07-18
US11827642B2 (en) 2023-11-28
US9200002B2 (en) 2015-12-01
RS57542B1 (sr) 2018-10-31
IL244677A0 (en) 2016-04-21
SMT201800448T1 (it) 2018-09-13
ZA201601970B (en) 2019-06-26
HK1221461A1 (zh) 2017-06-02
CY1121182T1 (el) 2020-05-29
HUS2100006I1 (hu) 2021-03-29
CA2926999A1 (en) 2015-04-23
PL3057969T3 (pl) 2018-11-30
US20230129944A1 (en) 2023-04-27
PH12016500611A1 (en) 2016-06-13
JP6782756B2 (ja) 2020-11-11
CN105658652A (zh) 2016-06-08
RU2016118768A3 (lt) 2018-06-21
CA2926999C (en) 2021-10-19
LTPA2021003I1 (lt) 2021-04-12
US9994575B2 (en) 2018-06-12
NL301094I2 (nl) 2021-03-18
EP3057969A1 (en) 2016-08-24
ES2683127T3 (es) 2018-09-25
UY35787A (es) 2015-04-30
KR102378689B1 (ko) 2022-03-24
HUE059041T2 (hu) 2022-10-28
JP6446040B2 (ja) 2018-12-26
LT3057969T (lt) 2018-07-10
AU2014337314A1 (en) 2016-04-07
IL244677B (en) 2019-10-31
DK3057969T3 (en) 2018-09-24
US20150111887A1 (en) 2015-04-23
CN110003217B (zh) 2022-10-18
RU2706235C2 (ru) 2019-11-15
NZ718075A (en) 2021-10-29
US10807985B2 (en) 2020-10-20
US20170204104A1 (en) 2017-07-20
HRP20181388T1 (hr) 2018-10-19
NO2021012I1 (no) 2021-03-18
CY2021007I2 (el) 2021-06-25
MX365614B (es) 2019-06-07
WO2015057873A1 (en) 2015-04-23
BR112016008541A2 (pt) 2017-09-12
TW201546062A (zh) 2015-12-16
AU2014337314B2 (en) 2018-12-13
MX2016004927A (es) 2016-07-11
JP2019048878A (ja) 2019-03-28
CN105658652B (zh) 2019-04-12
TWI683814B (zh) 2020-02-01
KR20160062173A (ko) 2016-06-01
US20190144454A1 (en) 2019-05-16
US12624043B2 (en) 2026-05-12
US20210284645A1 (en) 2021-09-16
ES2923888T3 (es) 2022-10-03
HUE039687T2 (hu) 2019-01-28
US20240317757A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
LTPA2021003I1 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su KIT
DK3074027T3 (da) Synergistiske bakteriesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
LT2961410T (lt) Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
HUE049637T2 (hu) Toalettben lehúzható katéterek
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
EP2889350A4 (en) ADHESIVE COMPOSITION
DK2943549T3 (da) Synergistisk h2s-scavenger-sammensætning
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK3027750T3 (da) Biokatalytisk sammensætning
EP3012292A4 (en) PROCESSING AGENTS AND COMPOSITION
DK2956010T4 (da) Fedtsammensætning
ES2651188T8 (es) Composición líquida fotopolimerizable
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
DK3498000T3 (da) MRS-konfiguration i to niveauer
HRP20181554T4 (hr) Tauroursodezoksikolna kiselina (tudca), namijenjena upotrebi u liječenju neurodegenerativnih poremećaja
ZA201507724B (en) The treatment of inflammatory disorders
PL3032022T3 (pl) Sposób montażu urządzenia ciągnącego i zestaw montażowy
GB2533234B (en) Ocular composition and kits thereof
LT3052625T (lt) Notch 1 specifinės sirnr molekulės
BR112015018892A2 (pt) kit ortopédico veterinario.
FR3007291B1 (fr) Composition cicatrisante et utlisation
DK3071282T3 (da) Kateterpunktursæt
HRP20181445T1 (hr) Sastavi i postupci za liječenje dijabetesa tipa 1